Park, Ji Eun
Jo, Jaemin
Youk, Jeonghwan
Kim, Miso http://orcid.org/0000-0002-4064-4199
Yoon, Soon Ho
Keam, Bhumsuk
Kim, Tae Min
Kim, Dong-Wan
Article History
Received: 31 May 2023
Accepted: 25 September 2023
First Online: 26 October 2023
Declarations
:
: This study was approved by the institutional review board (IRB No. 2001-069-1094) and was conducted according to the Declaration of Helsinki. The requirement for obtaining consent was waived by the IRB.
: Not applicable.
: MK received consulting fees from Merck Sharp & Dohme Corp., Ipsen, Bristol-Myers Squibb/Ono Pharmaceutical, Eisai, Boryung, and Yuhan outside the submitted work. TMK received honoraria from or played an advisory role with AstraZeneca; Boryung; F. Hoffmann-La Roche Ltd./Genentech, Inc.; IMBDx, Inc.; Janssen; Novartis; Regeneron; Samsung Bioepis; Sanofi; Takeda; and Yuhan and received research funding from AstraZeneca-Korea Health Industry Development Institute outside the submitted work. SHY works as a chief medical officer in MEDILCAL IP and has a stock option for the firm. The other authors declare that they have no competing interests.Seoul National University Hospital has received research funding from Alpha Biopharma, Amgen, Astrazeneca/Medimmune, Boehringer-Ingelheim, Bridge BioTherapeutics, Chong Keun Dang, Daiichi-Sankyo, GSK, Hanmi, Janssen, Merck, Merus, Mirati Therapeutics, MSD, Novartis, ONO Pharmaceutical, Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, Yuhan, and Inno outside the submitted work.